title: Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping.
abstract: Non-small cell lung cancers (NSCLC), in particular adenocarcinoma, are often mixed with normal cells. Therefore, low sensitivity of direct sequencing used for K-Ras mutation analysis could be inadequate in some cases. Our study focused on the possibility to increase the detection of K-Ras mutations in cases of low tumour cellularity. Besides direct sequencing, we used wild-type hybridisation probes and peptide-nucleic-acid (PNA)-mediated PCR clamping to detect mutations at codons 12 and 13, in 114 routine consecutive NSCLC frozen surgical tumours untreated by targeted drugs. The sensitivity of the analysis without or with PNA was 10 and 1% of tumour DNA, respectively. Direct sequencing revealed K-Ras mutations in 11 out of 114 tumours (10%). Using PNA-mediated PCR clamping, 10 additional cases of K-Ras mutations were detected (21 out of 114, 18%, P<0.005), among which five in samples with low tumour cellularity. In adenocarcinoma, K-Ras mutation frequency increased from 7 out of 55 (13%) by direct sequencing to 15 out of 55 (27%) by clamped-PCR (P<0.005). K-Ras mutations detected by these sensitive techniques lost its prognostic value. In conclusion, a rapid and sensitive PCR-clamping test avoiding macro or micro dissection could be proposed in routine analysis especially for NSCLC samples with low percentage of tumour cells such as bronchial biopsies or after neoadjuvant chemotherapy.
authors.affiliation: Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de Hautepierre, Centre Hospitalier Universitaire de Strasbourg, 67098 Strasbourg Cedex, France. Michele.FALLER@chru-strasbourg.fr
authors.forename: M
authors.initials: M
authors.lastname: Beau-Faller
authors.forename: M
authors.initials: M
authors.lastname: Legrain
authors.forename: A-C
authors.initials: AC
authors.lastname: Voegeli
authors.forename: E
authors.initials: E
authors.lastname: Guérin
authors.forename: T
authors.initials: T
authors.lastname: Lavaux
authors.forename: A-M
authors.initials: AM
authors.lastname: Ruppert
authors.forename: A
authors.initials: A
authors.lastname: Neuville
authors.forename: G
authors.initials: G
authors.lastname: Massard
authors.forename: J-M
authors.initials: JM
authors.lastname: Wihlm
authors.forename: E
authors.initials: E
authors.lastname: Quoix
authors.forename: P
authors.initials: P
authors.lastname: Oudet
authors.forename: M P
authors.initials: MP
authors.lastname: Gaub
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D011905:Genes, ras; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009693:Nucleic Acid Hybridization; D020135:Peptide Nucleic Acids / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000379:methods*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D012680:Sensitivity and Specificity; D018631:ras Proteins / Q000235:genetics*
chemical_list: C117307:KRAS protein, human; D020135:Peptide Nucleic Acids; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins